Cancer discovery

publication venue for

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer. 2019
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. 2018
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF^V600E-Mutant Brain Tumor. 2018
An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. 2017
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. 2015
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. 2012
The DNA Damage Response and Inflammation in Cancer.. 13. 2023
Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer. 2023
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma.. 13. 2023
African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent.. 12. 2022
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.. 12. 2022
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia.. 12. 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.. 12. 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.. 12. 2022
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.. 12. 2022
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.. 12. 2022
SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.. 12. 2022
Enhancing the Trajectories of Cancer Health Disparities Research: Improving Clinical Applications of Diversity, Equity, Inclusion, and Accessibility.. 12. 2022
Cancer-Causative Mutations Occurring in Early Embryogenesis.. 12. 2022
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.. 12. 2022
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.. 11. 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.. 11. 2021
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.. 11. 2021
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.. 11. 2021
Discovery of Candidate DNA Methylation Cancer Driver Genes.. 11. 2021
Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women.. 11. 2021
NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.. 11. 2021
Genomics and Cancer Disparities: The Justice and Power of Inclusion.. 11. 2021
LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms.. 11. 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.. 11. 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.. 11. 2021
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence.. 11. 2021
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.. 11. 2020
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies.. 11. 2020
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.. 11. 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.. 11. 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.. 11. 2020
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.. 10. 2020
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants.. 10. 2020
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.. 10. 2020
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2^V617F-Mutant MPN.. 10. 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.. 10. 2020
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.. 10. 2020
Lineage Reversion Drives WNT Independence in Intestinal Cancer.. 10. 2020
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.. 10. 2020
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer.. 10. 2020
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.. 10. 2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.. 10. 2020
Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas.. 10. 2020
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.. 10. 2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.. 10. 2020
Pan-Cancer Efficacy of Vemurafenib in BRAF ^V600-Mutant Non-Melanoma Cancers.. 10. 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.. 10. 2020
Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.. 9. 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.. 9. 2019
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.. 9. 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.. 9. 2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.. 9. 2019
BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.. 9. 2019
Correction: An Acquired HER2 ^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.. 9. 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.. 9. 2019
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.. 9. 2019
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.. 9. 2018
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.. 9. 2018
Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models.. 9. 2018
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.. 8. 2018
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.. 9. 2018
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. 8. 2018
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.. 8. 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.. 8. 2018
Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.. 8. 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 ^c259T Cells in Synovial Sarcoma.. 8. 2018
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.. 8. 2018
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.. 8. 2018
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.. 8. 2018
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.. 8. 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF^V600E-Mutant Colorectal Cancer.. 8. 2018
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.. 8. 2018
Accelerating Discovery of Functional Mutant Alleles in Cancer.. 8. 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.. 8. 2017
Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. 8. 2017
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.. 8. 2017
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.. 8. 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.. 7. 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.. 7. 2017
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.. 7. 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.. 7. 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.. 7. 2017
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. 7. 2017
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. 7. 2017
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. 7. 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.. 7. 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).. 7. 2017
The Genetic Basis of Hepatosplenic T-cell Lymphoma.. 7. 2017
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.. 7. 2016
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.. 7. 2016
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.. 7. 2016
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. 7. 2016
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.. 6. 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.. 6. 2016
Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.. 6. 2016
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.. 6. 2016
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.. 6. 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.. 5. 2015
PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.. 5. 2015
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.. 5. 2015
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.. 5. 2015
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.. 5. 2015
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.. 5. 2015
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.. 5. 2015
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.. 5. 2015
The genetics of splicing in neuroblastoma.. 5. 2015
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.. 5. 2015
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.. 5. 2015
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.. 5. 2014
Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.. 4. 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.. 4. 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. 4. 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.. 4. 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.. 4. 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.. 4. 2014
Acquired initiating mutations in early hematopoietic cells of CLL patients.. 4. 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.. 4. 2014
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.. 4. 2014
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.. 4. 2014
Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion.. 4. 2014
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.. 4. 2014
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.. 4. 2014
Towards a unified model of RAF inhibitor resistance.. 4. 2014
Androgen receptor signaling regulates DNA repair in prostate cancers.. 3. 2013
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. 3. 2013
ERK pathway inhibitors: how low should we go?. 3. 2013
ZNF365 promotes stability of fragile sites and telomeres.. 3. 2013
Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine.. 3. 2013
Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.. 3. 2013
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.. 3. 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.. 3. 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.. 3. 2013
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.. 3. 2012
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.. 3. 2012
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.. 2. 2012
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.. 2. 2012
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.. 2. 2012
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.. 2. 2012
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.. 2. 2012
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.. 2. 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.. 2. 2012
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.. 2. 2012
miR-23a promotes the transition from indolent to invasive colorectal cancer.. 2. 2012
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.. 2. 2012
MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer.. 2. 2012
Genomic complexity and AKT dependence in serous ovarian cancer.. 2. 2012
Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.. 1. 2011
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.. 2. 2011
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. 1. 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.. 1. 2011
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.. 1. 2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.. 1. 2011
Characterization of KRAS rearrangements in metastatic prostate cancer.. 1. 2011
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.. 1. 2011
Optineurin Guards IFNγ Signaling in Cancer Cells. 2021
Revealing ARID1A Function in Gastric Cancer from the Bottom Up. 2021
Malignant Gliomas: Simplifying the Complexity. 2019
An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming? 2019
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer. 2019
Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. 2018
Quantifying the Benefits of Genome-Driven Oncology. 2017
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next? 2016
Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas. 2016
Tracing the roots of cancer evolution. 2014
Discovering what makes STAT signaling TYK in T-ALL. 2013
STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable". 2012
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.. 13. 2023
WNT as a Driver and Dependency in Cancer. 2021
Tumor Immunity and Immunotherapy for HPV-Related Cancers. 2021
Artificial Intelligence in Cancer Research and Precision Medicine. 2021
Diffuse Glioma Heterogeneity and Its Therapeutic Implications. 2021
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. 2020
Precision Prevention and Early Detection of Cancer: Fundamental Principles. 2018
The Expanding World of N-MYC-Driven Tumors. 2018
Targeting ALK: Precision Medicine Takes on Drug Resistance. 2017
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. 2015
Patient-derived xenograft models: an emerging platform for translational cancer research. 2014
The basic principles of chimeric antigen receptor design. 2013
Negative feedback and adaptive resistance to the targeted therapy of cancer. 2012

VIVO Weill Cornell Medical College

Cancer discovery Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

Electronic International Standard Serial Number (EISSN)